pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›AUKELSO
drug
save

AUKELSO

Marketedupdated 3mo ago
by $HCWB HCW Biologics Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval8 co-mentions · 2 sources
  • companyBiocon Biologics Ltd4 co-mentions · 2 sources
  • drugdenosumab4 co-mentions · 2 sources
  • drugXgeva4 co-mentions · 2 sources

all catalysts(2)

approval · 2
Sep 16, 2025
approval
$HCWB
11mo ago
AUKELSO (DENOSUMAB-KYQQ) — FDA approval
AUKELSO
→
Oct 29, 2025
approval
$HCWB
10mo ago
AUKELSO (DENOSUMAB-KYQQ) — FDA approval
AUKELSO
→

News(0)

no news has mentioned this drug yet

brand
AUKELSO
generic
DENOSUMAB-KYQQ
MOA
12.1 Mechanism of Action Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid tumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANK receptor contributes to osteolysis and tumor growth. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 25m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?